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Background: The Human Immune Deficiency Virus (HIV) can manifest neurologically in both adults and children. Early
invasion of the central nervous system by the virus, affecting the developing brain, is believed to result in the most
common primary HIV-related neurological complication, HIV Encephalopathy (HIVE). In countries such as South Africa
where many children have not been initiated on antiretroviral treatment early, HIVE remains a significant clinical problem.
Methods: Children were selected from a clinic for children with neurologic complications of HIV, located at the Red Cross
War Memorial Children’s Hospital, South Africa 2008–2012. Eligible subjects fulfilled the following inclusion criteria: aged 6
months-13 years; positive diagnosis of HIV infection, vertically infected and HIVE as defined by CDC criteria. Each
participant was prospectively assessed by a Pediatric Neurologist using a standardized proforma which collated relevant
details of background, clinical and immunological status.
Results: The median age of the 87 children was 64 months (interquartile range 27–95 months). All except one child
were on antiretroviral treatment, 45% had commenced treatment <12 months of age. Delayed early motor milestones
were reported in 80% and delayed early speech in 75% of children in whom we had the information. Twenty percent
had a history of one or more seizures and 41% had a history of behavior problems. Forty-eight percent had microcephaly
and 63% a spastic diplegia. CD4 percentages followed a normal distribution with mean of 30.3% (SD 8.69). Viral loads
were undetectable (<log 1.6) in 70% of the children. Brain imaging was performed on 56% with 71% of those imaged
demonstrating at least one abnormality, most commonly white matter volume loss or signal abnormality.
Conclusions: Amongst the cohort of children referred to this clinic, the diagnosis of HIVE was unrecognized in the
general medical services, even in its most severe form. Developmental delay and school failure were major presenting
problems. Co-morbidities are a frequent finding and should be sought actively in order to optimize management and
promote best possible outcomes for this vulnerable group of children.
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According to the World Health Organization, approxi-
mately 3.4 million children worldwide are suffering from
Human immunodeficiency Virus (HIV) or Acquired im-
mune deficiency syndrome (AIDS) with >90% of them
residing in sub-Saharan Africa [1-3]. There are an* Correspondence: kirsty.donald@uct.ac.za
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not yet receiving antiretroviral therapy (ART), with an
estimated 48,000 new infections among children annu-
ally [2,3]. The greatest proportion of these figures repre-
sent vertically acquired HIV, which includes infection in
utero, at time of delivery and from breast milk [2].
The Western Cape, where the study was completed,
commenced its public sector prevention of mother-to-
child transmission (PMTCT) intervention programme in
2001. The initial PMTCT programme was based on the
HIVNET 012 nevirapine (NVP) regimen, and provision
of milk powder for all infants of mothers who elected to
formula-feed their offspring for the first 6 months of life.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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province was reached at the beginning of 2003. In mid-
2004 an intensified PMTCT programme was introduced
based on the CD4 count of all HIV-infected pregnant
women. Those women with CD4 count ≤ 200 cells/μL
were commenced on antiretroviral therapy (ART), while
those with a CD4 count >200 cells/μL were commenced
on zidovudine prophylaxis at 34–36 weeks gestation,
and during labour administered a single dose of NVP.
All infants born to HIV-infected mothers received a sin-
gle dose of NVP at birth plus a 7-day course of AZT [4].
Between 2004 and 2013 this programme underwent sev-
eral revisions including progressive liberalization of the
criteria used to initiate ART in pregnant women, intro-
duction of 6 week infant testing (previously 14 weeks),
introduction of extended NVP prophylaxis for all HIV-
exposed infants, promotion of breastfeeding, and the
withdrawal of free-formula milk in 2012 [5].
HIV can have neurological manifestations in both
adults and children. Early invasion of the central ner-
vous system (CNS) by the virus, affecting the developing
fetal and infant brain, is believed to result in the most
common primary HIV-related CNS complication, HIV
Encephalopathy (HIVE) [6]. In non-treated children
prevalence reports have ranged from 20 to 60% [7-14].
HIVE refers to the disease, damage or malfunction of
the brain caused by HIV-1. Static HIVE is an unchan-
ging type of encephalopathy, whereas, progressive HIVE
is associated with neuroregression. This complication
can be present before significant immunosuppression
has developed, however its presence in a child infected
with HIV constitutes an AIDS-defining illness, [15]
reflecting the severity of the disease. According to the
Center for Disease Control (CDC), encephalopathy must
include criteria in at least one of the following areas for
at least 2 months in the absence of a concurrent illness:
a) failure to attain or loss of developmental milestones
or loss of intellectual ability, b) impaired brain growth or
acquired microcephaly and/or c) acquired symmetric
motor deficit [15].
While substantial numbers of children have benefitted
from antiretroviral treatment (ART), significant barriers
to early ART initiation continue to exist, compared to
adults infected with HIV. This places untreated children
at risk, particularly of central nervous system (CNS) se-
quelae. HIV-1 invades the developing CNS earlier and
with greater severity than observed in adults [7-14]. In
addition patients on ART may remain vulnerable to the
effects of HIV on the brain because the CNS may be a
reservoir for persistent viral replication [16].
Reported specific neurodevelopmental delays in young
children associated with HIVE include delays in acquir-
ing early motor and language skills [6,17,18]. These have
included general gross motor skills and developmentco-ordination, muscle tone and deep tendon reflexes. In
older children specific cognitive deficits, impaired motor
skills and decreased language ability are also reported.
Cognitive deficits include verbal and memory impairment
and difficulty with visual-spatial integration and executive
function [19,20].
Neuroimaging studies using more recently available
quantitative magnetic resonance imaging (MRI) tech-
niques are contributing to improved understanding of
the underlying neurobiology of the primary effects of
HIV on the developing brain. In a study by Ackermann
et al., the findings of white matter signal abnormalities
in a significant proportion of the brains of young chil-
dren (mean age: 31.4 months) initiated on ART under 3
months of age, may indicate that infiltration of the CNS
by HIV occurs at an extremely early stage of infection
[21]. These abnormalities are much more subtle than
the global cerebral atrophy and or basal ganglia calcifica-
tions which are more typically described in the context
of children with HIV encephalopathy (HIVE) [22]. In
addition, two recent studies have reported subtle white
matter microstructural abnormalities [23] and neuro-
chemical abnormalities [24] in relatively well older chil-
dren. In particular, Hoare et al. reported an association
between poor performance on tests of executive function
and attention with reduced white matter integrity in the
corpus callosum in “slow-progressor” children who were
considered too well to require ART. These white matter
changes represent a variable combination of diffuse mye-
lin loss, astroglial proliferation, and infiltration by mono
and multinucleated macrophages [25]. Methods such as
those described above, which can detect more subtle
changes in especially white matter integrity, may be key
in the investigation of both the timing and natural his-
tory of neurological complications of HIV. However,
despite this emerging literature there remains a paucity
of data from low and middle income countries (LMIC)
where the utility of these investigations in a clinical con-
text with high burden of disease, but limited resources
and consequent different standard of care remains inad-
equately explored.
HIVE was found to be the most common primary
neurological disorder of HIV infected children diagnosed
in the HIV Neurology clinic at Red Cross War Memorial
Children’s Hospital and in this report we aimed to de-
scribe this group of children in order to better under-
stand their profile as well as identify challenges and




This paper offers a descriptive profile of HIV infected
children referred to a dedicated HIV-Neurology Clinic in
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overall purpose of this clinic is to screen children identi-
fied by clinicians to be at risk for neurologic complica-
tions of HIV. Children are evaluated, investigated and a
formal neurologic diagnosis given where appropriate.
Following this there is a formulation of on-going care
plans for these children. As part of the service a
database has been collected to help understand the
neurologic disease spectrum and demographics of our
population group. The health system in South Africa
is three-tiered such that the majority of children on
ARTs receive treatment at a primary level, where ac-
cess to neuro-imaging and neuro-cognitive testing is
not available. Red Cross War Memorial Children’s
Hospital is a tertiary level service with access to these
facilities. Referrals to the HIV-Neuro clinic come from
primary, secondary and tertiary levels. In addition to
the specific neurologic conditions such as epilepsy and
the complications of secondary CNS infections (primar-
ily tuberculous and other bacterial meningitides), rea-
sons for referral to this clinic include general concerns
about developmental delay, particularly delay in onset
of walking beyond 2 years, learning difficulties and be-
havior problems such as memory loss, hyperactivity,
poor concentration and not referred as HIVE per se.
Children were selected from this clinic over the period
2008–2012. Eligible subjects were those who had attended
the HIV Neurology clinic at least once and who fulfilled
the following inclusion criteria: aged between 6 months
and 13 years; positive diagnosis of HIV infection (includes
initial and confirmatory tests), vertical transmission and
HIVE as defined by CDC criteria. Children were excluded
when they had a history of: an uncontrolled medical con-
dition, such as the presence of an identified CNS condi-
tion (other than HIV), CNS infections e.g. Tuberculous
Meningitis; drug or alcohol exposure in pregnancy; history
of a head injury with loss of consciousness greater than 5
min or any radiological evidence of skull fracture; history
of perinatal complications such as hypoxic ischemic en-
cephalopathy or neonatal jaundice requiring exchange
transfusion, or neurodevelopmental and or neuroregres-
sive or genetic disorder not attributed to HIV.
Data collection
Each participant was prospectively assessed by a medical
specialist (KD or KW) using a standardized proforma
which collated relevant details of background, clinical
and immunological status information. Background in-
formation was collected from the care-giver at the time
of assessment, though if supplementary information was
available in the medical folder this was also included.
Details included source of referral, age, sex, birth history
(antenatal, birth complication, gestation and birth weight),
past medical, early developmental history and a history ofcaregivers. In addition, care-givers were asked about the
child’s home environment and schooling situation. This
information was based on caregiver recall, although with
respect to identifying age of achieving milestones a time-
line follow-back approach was used to achieve best pos-
sible recall.
Clinical assessments performed included anthro-
pometry (height, weight, head circumference (OFC)),
full neurological and physical examination (indications
of spastic diplegia and or long tract signs, microceph-
aly, peripheral neuropathy, visual and hearing impair-
ment and child’s mood). In addition, immunological
results collected consisted of most recent CD4 and
viral load counts. Due to the disparate facilities from
which the children had received their primary ART,
information on immunological status at time of HIV
diagnosis and ART commencement was available on
too few children to include in the analysis.
Children selected for this study were also referred for
either Computer Tomography (CT) or Magnetic reson-
ance imaging (MRI) of the brain using the standard clin-
ical neuroimaging protocol used at the hospital. These
images were analyzed and reported by a Pediatric Neu-
roradiogist (TK) at Red Cross War Memorial Children’s
Hospital. Informed consent is part of the protocol for
MRI acquisition in young children. Due to the difficult
socio-economic environments from which HIV infected
children in South Africa generally come, as well as the
high burden of medical appointments they are required
to attend, failure to attend hospital appointments (par-
ticularly when the visit is not directly related to the
management of HIV itself ) is extremely common. This
was the most common reason for children not having
neuroimaging.
Collected information was anonymized and entered
onto a password protected database in a private office.
Ethical approval was obtained from the University of
Cape Town Human Research Ethics committee (UCT
HREC 126/2011).
Statistical analysis
Background information, results of clinical assessments,
immunological and imaging findings were analyzed by
using Stata version 12 (Stata Corp LP, 4905 Lakeway
Drive, College Station, Texas 77845 USA). All continu-
ous data was assessed for normality using the Shapiro
Wilk test, and parametric or non-parametric summary
measures were reported as appropriate.
To determine if there was significant association be-
tween the age of starting ART and physical findings of
microcephaly and spastic diplegia, the statistician com-
pared the median age at ART commencement with two
groups (positive or negative diagnosis) using the Wilcoxon
rank-sum (Mann–Whitney test). This analysis was also
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munological status and these physical findings.
In addition, analysis was done to determine whether
there was an association between imaging abnormalities
described in the cohort and the HIVE-defining physical
findings of microcephaly and spastic diplegia, age at
ART commencement and current immunological status.
For each association prevalence ratios were estimated by
using generalized linear regression.
Statistical significance level was set at p < 0.05.
Results
Study cohort background information
The algorithm as presented in Figure 1 provides an over-
view of the number of children identified, selected and
included for proforma assessment and neuroimaging
procedures. During the study period 145 children were
seen in the HIV Neurology clinic, of which 87 children
fulfilled the criteria for eligibility (HIVE) and were
included in this study. The remaining 58 children had
other neurological complications of HIV such as cerebro-
vascular events, severe epilepsy or a background of other
complicating medical factors (especially opportunistic CNS
infections, perinatal complications and history of maternalFigure 1 Study algorithm.substance use in pregnancy) which excluded an isolated
diagnosis of HIVE. Only children who were diagnosed with
HIVE were included in the analysis. Twenty nine of the 87
children were referred from primary health care clinics, 35
from secondary level hospitals and 23 from other clinics or
wards at RCWMCH. Analysis of carer consistency showed
11 had consistent care with 2 parents, 38 had consistent
care with one parent and 37 had had multiple carers during
this time (which may have included a parent during some
of that time).
Table 1 provides an overview of the background infor-
mation of the HIVE study cohort. The median age of the
children was 64 months interquartile range (IQR) of 27
to 95 months, with the majority aged between 2–9 years
(87%). All except one child were on ART at time of first
assessment, and 38 children (45%) had first received
ART before the age of 12 months. Of the 87 children in-
cluded, 85 were referred to the clinic as a result of con-
cern regarding their failure to attain early developmental
milestones, school failure or behavioral problems, but
were not formally diagnosed with HIVE prior to being
seen at the HIV-Neurology clinic.
With regards to the early milestones, delayed walking
was reported in 60/75 children (80%) and delayed early
Table 1 Background information for children with HIVE




Gender (n = 87)
Male 51 59
Female 36 41
Age group at examination (n = 87)
<2 years 16 18
2 – 4 years 24 28
5 – 9 years 36 41
10 – 14 years 11 13
Age at ART commencement (n = 87)
<12 months 38 44
12 – 36months 33 38
>36 months 14 16
Not reported 2 2
Developmental milestone walking (n = 75)
On time 15 20
Delayed (>18 months) 60 80
Not old enough to tell 5 N/A
Not reported 7 N/A
Developmental milestone talking (n = 72)
On time 18 25
Delayed (>18 months) 54 75
Not old enough to tell 4 N/A
Not reported 11 N/A
Home environment (n = 87)
home 49 56
Institution, orphanage, foster home 13 15
bio foster (adopted by family member) 20 23
other foster 4 5
Not reported 1 1
School (n = 87)
Mainstream pre-school 32 37
Mainstream school 35 40
Special school/care center 4 5
None 7 8




Not reported 23 26
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whom a medical history was available 17 children (20%)
had a history of one or more seizure and 14 (17%) had
already been assigned a formal diagnosis of attentiondeficit hyperactivity disorder by their treating doctor
when they were referred to the clinic. In addition, 33
children (41%) had a history of behavior problems as re-
ported by their parents. Sixty-seven (86%) children were
attending a mainstream educational facility at the time
of assessment and more than half of the children of
school-going age (57%) had had to repeat a school-year
or was not age appropriate for their current school
grade. All participants were of low socioeconomic status
and 37 (43%) of them were living in a foster or adopted
home environment.
Clinical information
Anthropometric measures weight, height and head cir-
cumference were at least 2 standard deviations below
that expected for age in more than half of the study-
cohort. Of the 87 children who underwent physical
exam, 42 children (48%) presented with microcephaly
(head circumference <2standard deviations from the age
norms on WHO growth charts), 55 (63%) with spastic
diplegia. Thirty-three children (37%) had active ear dis-
ease (chronic otitis media). Clinical findings are detailed
in Table 2.
Immunological status
Recent CD4 count (percentage) and viral loads (log value)
were available for 70 and 71 children with HIVE respect-
ively. All the children about whom we had immunological
information were on ART at the time of assessment. CD4
percentages followed a normal distribution with mean of
30.3% (SD 8.69). Viral loads were undetectable (<log 1.6)
in 50 (70%) of the children. The mean viral load was log
2.07 (IQR 1.3-2.3).
Neuroimaging
Brain imaging was successfully performed on 49 of the
87 (56%) children. Five children received both MRI and
CT scans (their findings are aggregated) and 4 children
failed their scan and so their findings are not reported,
making up the total of 58 scans recorded in Figure 1.
Fourteen children had normal scans, while 35 (71%) pre-
sented with at least one abnormality, six children with a
combination of two abnormalities, two children with
three abnormalities and three children with four abnor-
malities. Table 3 gives an overview of the CT and MRI
imaging findings reported in the HIVE study-cohort and
Figures 2 and 3 show examples of the most common
neuroimaging findings.
Associations with microcephaly and spastic diplegia
There was no statistically significant difference in age at
starting ART between those with and without micro-
cephaly (p = 0.4, Wilkoxon rank-sum (Mann–Whitney
test), z = −0.87). Similarly for spastic diplegia, there was






3rd – 10th centile 16 18
<3rd centile 28 32
Height
Normal 24 28
3rd – 10th centile 20 23
<3rd centile 26 30
Not recorded 17 20
Physical exam
Spastic diplegia/long tract signs 55 63
Microcephaly 42 48
Learning Difficulties 6 7
Peripheral Neuropathy 1 1
Visual impairment 1 1
Hearing impairment 2 2
Ears
Normal 36 41
Acute otitis media 7 8
Chronic suppurative otitis media 26 30
not examined/recorded 16 18
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between those with and without spastic diplegia, although
this approached significance (p = 0.06, Wilkoxon rank-
sum (Mann–Whitney test), z = 1.83).There was no in-
creased relative risk for a particular imaging abnormality
with this group. Neither recent CD4 percentage values
nor the presence/absence of detectable viral load corre-
lated with the presence of particular neuroimaging find-





Global Atrophy 10 20
Basal Ganglia Calcifications 4 8
White Matter Signal Change 9 18
White Matter Volume Loss 12 24
Grey Matter Volume Loss 4 8
Thinning of Corpus Callosum 9 18
Other 6 12
Normal 14 29Discussion
This study describes the clinical, immunological and im-
aging features of a clinical group of 87 children with
HIVE attending a dedicated referral clinic for children
with neurologic complications of HIV infection. Current
figures clearly demonstrate the major burden of child-
hood HIV is carried by countries in sub-Saharan Africa.
It is apparent that even in South Africa where the roll-
out of ART to both HIV infected children and adults,
has improved the outlook for children, HIVE remains a
problem in clinical practice.
We established that amongst the cohort of children re-
ferred to us, the specific diagnosis of HIVE is frequently
unrecognized in general medical services, even in its
most severe form. Postulated reasons for this include
busy clinics where the time taken to do a full neurology
examination is difficult to find, or where clinicians,
though recognizing the problem, referred the children
for more detailed assessment in order to exclude other
causes of the neurology problems in this group. Pediatric
services and in particular more specialized neurology
services are particularly under-represented across the
African continent [26]. This implies that the milder
forms are probably being missed in overburdened health
systems such as that in South Africa and other resource-
limited countries.Figure 2 Axial CT Brain showing bilateral basal ganglia
calcification and cerebral shrinkage in a 1year old child
with HIVE.
Figure 3 Axial T2 (a) and FLAIR (b) images of an HIV-positive child showing bilateral symmetrical high signal in the periventricular
white matter with normal basal ganglia. Prominence of the cerebral sulci implies volume loss.
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in HIV-infected children varies between 8 to >60% de-
pending on the measures used and clinical populations
[10,11,17,19,27,28]. Evidence is emerging that even chil-
dren started on effective ART at a very young age, may
demonstrate adverse neurologic outcomes in later child-
hood [18,20,21]. The presence of a history of delayed
early motor and language milestones in the vast majority
of this cohort is to be expected as their diagnosis pre-
selects them into a severely affected group. However,
this history of these delays suggest that the CNS damage
in these children was present from early infancy and that
despite almost uniformly good viral control at time of
assessment, the residual effects of the virus on the devel-
oping neurological system is likely to be long-lasting.
Although with formal neuropsychological testing some
of the children excluded from the diagnosis of HIVE in
this cohort might have met criteria for the diagnosis,
there will remain a group whose overall cognitive per-
formance falls within the normal range (or within 2 SDs
of the norm), but who have specific learning difficulties.
Evidence for this spectrum of subtler neurocognitive
effects is described in even completely asymptomatic
children [23]. The concept of a “milder” form of neuro-
cognitive disturbances in HIV infected children such as
the adult condition of HIV-associated neurocognitive
disorder (HAND) is recognized but is yet to achieve a
consensus definition in children and adolescents. This
condition may have significant effects in functional
terms on the learning potential of the child (especially at
school). This is a critical discourse, as it is likely to be
important in informing treatment guidelines for these
children especially in contexts where access to treatment
may depend on clinical criteria. Although our olderchildren did not consistently undergo formal neuro-
psychological testing, a significant proportion of these
children were repeating grades at school. This can be
regarded as a manifestation of functional neurocognitive
compromise.
Co-morbidities were found to be significant manage-
ment issues in this group of children with HIVE. Twenty
percent had suffered one or more seizures, 40% had re-
ported behavior problems with 18% a formal diagnosis
of ADHD and 39% had active ear disease. Relatively
“minor” conditions such as recurrent ear infections,
which are inadequately managed, can affect a child’s
hearing. Even mild hearing loss in this complex disorder
where a child may have additional cognitive and or
learning difficulties, could have serious long-term effects
on their school outcome and future economic potential.
High prevalence of behavior problems amongst other
groups of children with chronic medical conditions is
well described. HIV integration into the frontal cortex
and connecting structures of the CNS are suggested as
possible mechanisms for specific behavioral manifesta-
tions in this group [29,30]. The figure reported here is in
keeping with some of the chronic physically disabling
conditions such as Duchenne muscular dystrophy and
other neuromuscular conditions (41%) where one may
expect there to be a higher prevalence [31]. The high
prevalence of co-morbidities in this group highlights the
importance of actively enquiring after and managing
these aspects of the child’s medical profile.
Although a definitive clinical or imaging predictor for
HIVE has not been defined, risk factors associated with
HIVE include maternal and child immune status, high
CSF and plasma viral load, high circulating monocytes,
timing of infection, route of transmission, and availability of
Donald et al. AIDS Research and Therapy  (2015) 12:2 Page 8 of 10early treatment [2,27,28]. This previously reported literature
has implicated high viral loads as a predictor for HIVE.
Over two thirds of our group had undetectable viral loads
at time of assessment so this made it a largely unhelpful
variable to use in our group. Information on peak viral
loads or viral loads at the time of diagnosis prior to ART
initiation may have been more helpful in this analysis. Of
interest there was no statistically significant association be-
tween age at starting ART and the presence of microceph-
aly, though the association between age at starting ARTand
spastic diplegia approached significance in this group. Chil-
dren manifesting spastic diplegia as their neurological cri-
terion for HIVE are likely to represent the severe end of the
spectrum of the disorder and the trend towards association
with delayed ART in this group is consistent with studies
which have demonstrated poorer neurological outcomes in
children with deferred ART initiation [18].
Imaging findings described in HIVE have focused on a
number of characteristics. These include Computer
Tomography (CT) findings of generalized atrophy, ven-
triculomegaly, and basal ganglia calcification [32-35].
Although these are the most commonly reported signs
of HIVE on CT scan; they appear not to be that com-
mon in absolute terms amongst children with HIVE and
may represent the severe end of the spectrum of the dis-
order. Magnetic Resonance Imaging (MRI) studies have
shown white matter microstructural changes amongst
HIV-infected, but not encephalopathic children [23,35].
Neuroimaging changes in the brains of HIV-infected
children could represent important indicators of disease.
A study showed correlations between changes in the
corpus callosum and significant reduced executive func-
tion and attention tests, as well as relations between
changes in superior longitudinal fasiculus and reduced
functional performance [23]. On the other hand, in an-
other older study, 76% of asymptomatic HIV-positive
children were found to have at least one abnormality of
global atrophy as well as more specific white matter
changes on brain CT scan [32]. Very few of these studies
have correlated the neuroimaging findings with neuro-
logical findings in the children they describe. In our
cohort, clinical neuroimaging sequences, even in an ex-
perienced specialist unit did not correlate usefully with
physical findings. A large proportion of scans (29%) were
completely normal despite all the children having abnormal
neurological findings suggestive of upper motor neuron
pathology (microcephaly and or spastic diplegia). It is prob-
able that more sophisticated MRI techniques such as diffu-
sion tensor imaging would be able to identify abnormalities
in white matter integrity at a microstructural level, however
this is not likely to represent a practical clinical approach in
our setting in the foreseeable future.
Introduction of ART is associated with prolonged sur-
vival rates of children suffering from HIV by promotinga broad spectrum of general and specific health mea-
sures including normal growth and development, im-
proved immunity, reduced risk of and vulnerability to
infections [36,37]. Its essential role in the effective man-
agement of the disease is now undisputed. ART is also
associated with dramatically decreased the prevalence of
HIVE in the United States from 35-50% to less than 2%
[2,38]. Furthermore, early initiation of ART results in
improved neurodevelopmental outcomes compared to
deferred initiation [18]. However, in resource-limited
contexts such as South Africa, where ART is not always
easily accessible and treatment is frequently delayed
beyond infancy, HIVE remains an important and fre-
quently undiagnosed clinical problem.
Limitations of our study include relatively small sam-
ple size and cross-sectional study design. All data was
captured from a data-base of a working clinic at a ter-
tiary centre in South Africa. The vast majority of HIV
infected children are primarily treated at primary level
health institutions which are staffed by medical officers
and not pediatricians or sub-specialists in neurology,
child psychiatry or developmental pediatrics and where
the burden of attending to the immediate life-threatening
medical issues are likely to result in only the severe devel-
opmental or behavioral issues being identified. As a result,
the relatively small number of children in this report is
likely to represent superficial evidence of a much larger
under-recognized problem. Another significant limitation
includes the fact that behavioral history and psychosocial
information was collected via carer report rather than
standardized testing and represents the reality of what
even a specialized clinic is able to offer in the clinical set-
ting in the present environment. However, both clinicians
who assessed the children are experienced in addressing
this scope of problem and the time-line follow-back
method was used to optimize parental recall where appro-
priate. In addition, the lack of formal neurocognitive eval-
uations on the older age group of children presenting to
the clinic means that the diagnosis of HIVE was made on
one of the two physical CDC criteria. As such this group
of 87 children most likely represents the more severe end
of the HIVE spectrum (i.e. all the children with a diagnosis
of HIVE had an abnormal neurological examination, mak-
ing analysis for clinical predictors very difficult). The lack
of useful clinical associations between physical findings
and immunological or imaging findings is not entirely sur-
prising given the cross-sectional study design and particu-
lar cohort.
Conclusion
The assessment of this group of children revealed some
useful insights for clinical practice. Regular anthropo-
metric measurements including height and head circum-
ference should be recorded in order to identify children
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of HIVE where appropriate. Structural neuroimaging
may not be helpful in the day-to-day management of a
significant group of children with HIVE. It is however,
useful in excluding secondary conditions where indi-
cated, especially where long tract signs are present such
as spastic diplegia. School failure is a major problem in
this group and in a society where HIV remains highly
stigmatizing and the school is frequently not aware of
the child’s diagnosis, many parents are reluctant to seek
help for their child’s learning problems. Co-morbidities
are a frequent finding in the South African setting and
need to be sought actively in order to optimize manage-
ment and promote best possible educational outcomes
for this vulnerable group of children.
Recently circulated national guidelines for the initi-
ation of ART in South Africa now recommends blanket
treatment for the <60 month age group (with older chil-
dren needing to meet clinical or immunological criteria).
However, until this year, official national policy only rec-
ommended immediate treatment for infants under 12
months of age [39]. As a result there is still a large pool
of children who would not have been included in the
blanket ART initiation group and who remain untreated
and vulnerable to the effects of the virus on the develop-
ing central nervous system. This study highlights that in
order to improve the quality of life of these children
earlier diagnosis of neurological risk at primary health
care levels is needed.
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